Considerations and challenges in defining optimal iron utilization in hemodialysis
about
Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st CenturyEfficiency of Original versus Generic Intravenous Iron Formulations in Patients on HaemodialysisUnderstanding the Recent Increase in Ferritin Levels in United States Dialysis Patients: Potential Impact of Changes in Intravenous Iron and Erythropoiesis-Stimulating Agent DosingEffects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial.Targets for adapting intravenous iron dose in hemodialysis: a proof of concept studyThe Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationaleRoxadustat (FG-4592): Correction of Anemia in Incident Dialysis PatientsCombination with intravenous iron supplementation or doubling erythropoietin dose for patients with chemotherapy-induced anaemia inadequately responsive to initial erythropoietin treatment alone: study protocol for a randomised controlled trial.Signal-intensity-ratio MRI accurately estimates hepatic iron load in hemodialysis patients.Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers.Iron-based phosphate binders--a new element in management of hyperphosphatemia.The Labile Side of Iron Supplementation in CKDManagement of the Dialysis Patient with Sickle Cell Disease.Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations.Investigational therapies for renal disease-induced anemia.Impact of iatrogenic iron overload on the course of hepatitis C in the dialysis population: A plea for caution.Target-based Anemia Management with Erythropoiesis Stimulating Agents (Risks and Benefits Relearned) and Iron (Still More to Learn).Ferric pyrophosphate citrate as an iron replacement agent for patients receiving hemodialysis.Serum Ferritin Variations and Mortality in Incident Hemodialysis Patients.Longitudinal trends in serum ferritin levels and associated factors in a national incident hemodialysis cohort.Is It Too Much of a Good Thing? A New Era in Phosphate Binder Therapy in ESRD.Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate.Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation.Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey.Anemia in chronic kidney disease.Very low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients.Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease
P2860
Q26752664-AF6E0392-375C-40B9-B223-3F9D203A1BC2Q28547636-69E6B3EC-35A1-40FB-A86D-89B6BED1A1A2Q36123635-24041DDF-1B37-453C-B4EC-936792D88677Q36194460-86170AFB-FA26-40EC-9E4E-53EED103D279Q36315311-E857CE9A-F90C-4B9C-BB17-198A07369174Q36333126-C282DE2F-2DCB-4672-8963-1F4A923F9405Q36746098-1034D1DD-B696-4680-88D9-1A0EEB937D82Q37355996-981CE2AC-080A-491D-871B-684201D6DC31Q37570855-8F5784E1-D53E-4FA8-9A95-759E27A72BF1Q37664189-70F3E83E-FE68-4973-ABFF-DBF47CFB0C25Q38295285-0CF716F7-D051-4CF0-8437-F1EB56DB8971Q38496987-F5402BB5-F8DB-4839-9E97-750ABC8FDFD9Q38547177-8EBEB902-950E-4E9E-A3E2-1E07575B0B18Q38761669-2386FD77-9DA9-4B86-8585-DC1E202FC62FQ38819455-93624EC5-F6C4-4ABE-89A2-9509A96109CBQ38884441-70EBB96B-C275-4748-BE92-62882505D189Q39022863-A4C0BCE6-BA97-4BE6-8B2D-31503CE42E69Q39216391-C5ACC5BD-6132-4861-B0BB-9EE90B760EDBQ40123974-AE6C2F08-A781-4B61-B21C-497EA9A51E73Q40340927-38187EEB-E159-43D7-8A25-CC6EB0BAC7CEQ43236775-346BFD54-58AD-447F-ACA2-13583F95DEFFQ45853530-75389B0E-FF21-4767-A384-EBDFD06A0D23Q47805747-462B471A-F2F8-47D9-A093-2F1FA0B77F8BQ48252464-B5E4DFFC-C5AE-4633-BFC5-420F8E237CA1Q53354670-ADED264C-720E-4586-9387-BF0F4D8C8BA0Q53823548-2F9A6948-150B-4282-AF7F-63B0C6CB5E59Q58700150-25D7BEAA-9765-4946-992E-693FBE755275
P2860
Considerations and challenges in defining optimal iron utilization in hemodialysis
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Considerations and challenges in defining optimal iron utilization in hemodialysis
@ast
Considerations and challenges in defining optimal iron utilization in hemodialysis
@en
Considerations and challenges in defining optimal iron utilization in hemodialysis
@nl
type
label
Considerations and challenges in defining optimal iron utilization in hemodialysis
@ast
Considerations and challenges in defining optimal iron utilization in hemodialysis
@en
Considerations and challenges in defining optimal iron utilization in hemodialysis
@nl
prefLabel
Considerations and challenges in defining optimal iron utilization in hemodialysis
@ast
Considerations and challenges in defining optimal iron utilization in hemodialysis
@en
Considerations and challenges in defining optimal iron utilization in hemodialysis
@nl
P2093
P2860
P3181
P356
P1476
Considerations and challenges in defining optimal iron utilization in hemodialysis
@en
P2093
A. M. Hung
C. P. Kovesdy
C. T. Chan
D. M. Charytan
D. W. Coyne
S. Fishbane
P2860
P304
P3181
P356
10.1681/ASN.2014090922
P407
P577
2015-06-01T00:00:00Z